Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.

Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.

Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545.

PMID:
22418661
2.

Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.

Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD.

Vaccine. 2011 Aug 5;29(34):5785-92. doi: 10.1016/j.vaccine.2011.05.040. Epub 2011 May 30. Review.

PMID:
21624411
3.

MF59&#x2122; as a vaccine adjuvant: a review of safety and immunogenicity.

El Sahly H.

Expert Rev Vaccines. 2010 Oct;9(10):1135-41. doi: 10.1586/erv.10.111. Review.

PMID:
20923265
4.

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.

Ahmed SS, Schur PH, MacDonald NE, Steinman L.

J Autoimmun. 2014 May;50:1-11. doi: 10.1016/j.jaut.2014.01.033. Epub 2014 Feb 19. Review.

5.

MF59 adjuvanted seasonal and pandemic influenza vaccines.

Tsai TF.

Yakugaku Zasshi. 2011;131(12):1733-41. Review.

6.

Aflunov(®): a prepandemic influenza vaccine.

Gasparini R, Amicizia D, Lai PL, Panatto D.

Expert Rev Vaccines. 2012 Feb;11(2):145-57. doi: 10.1586/erv.11.170. Review.

PMID:
22309663
7.

[Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic review of literature].

Ruiz-Aragón J, Grande Tejada AM, Márquez-Peláez S, Molina Linde JM, Yang R.

An Pediatr (Barc). 2013 Oct;79(4):208-17. doi: 10.1016/j.anpedi.2013.01.022. Epub 2013 Mar 13. Review. Spanish.

8.

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM.

Hum Vaccin Immunother. 2015;11(3):553-63. doi: 10.1080/21645515.2015.1011562. Review.

9.

The history of MF59(®) adjuvant: a phoenix that arose from the ashes.

O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD.

Expert Rev Vaccines. 2013 Jan;12(1):13-30. doi: 10.1586/erv.12.140. Review.

PMID:
23256736
10.

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A.

Influenza Other Respir Viruses. 2008 Nov;2(6):243-9. doi: 10.1111/j.1750-2659.2008.00059.x. Review.

11.

Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults.

Black S.

Vaccine. 2015 Jun 8;33 Suppl 2:B3-5. doi: 10.1016/j.vaccine.2014.11.062. Review.

12.

The avian influenza vaccine Emerflu. Why did it fail?

Young BE, Sadarangani SP, Leo YS.

Expert Rev Vaccines. 2015;14(8):1125-34. doi: 10.1586/14760584.2015.1059760. Epub 2015 Jun 22. Review.

PMID:
26098721
13.

Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Orsi A, Ansaldi F, de Florentiis D, Ceravolo A, Parodi V, Canepa P, Coppelli M, Icardi G, Durando P.

Hum Vaccin Immunother. 2013 Mar;9(3):582-90. Epub 2013 Jan 7. Review.

14.

Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis.

Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R.

Influenza Other Respir Viruses. 2011 Sep;5(5):299-305. doi: 10.1111/j.1750-2659.2011.00229.x. Epub 2011 Mar 21. Review.

15.

Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review.

Isai A, Durand J, Le Meur S, Hidalgo-Simon A, Kurz X.

Vaccine. 2012 Nov 19;30(49):7123-9. doi: 10.1016/j.vaccine.2012.09.032. Epub 2012 Sep 26. Review.

PMID:
23022149
16.

Inactivated influenza vaccines: recent progress and implications for the elderly.

Parodi V, de Florentiis D, Martini M, Ansaldi F.

Drugs Aging. 2011 Feb 1;28(2):93-106. doi: 10.2165/11586770-000000000-00000. Review.

PMID:
21275435
17.

Influenza virus vaccines: lessons from the 2009 H1N1 pandemic.

Broadbent AJ, Subbarao K.

Curr Opin Virol. 2011 Oct;1(4):254-62. doi: 10.1016/j.coviro.2011.08.002. Review.

18.

The mechanism of action of MF59 - an innately attractive adjuvant formulation.

O'Hagan DT, Ott GS, De Gregorio E, Seubert A.

Vaccine. 2012 Jun 19;30(29):4341-8. doi: 10.1016/j.vaccine.2011.09.061. Review. Erratum in: Vaccine. 2013 Apr 3;31(14):1877.

PMID:
22682289
19.

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.

Fox CB, Haensler J.

Expert Rev Vaccines. 2013 Jul;12(7):747-58. doi: 10.1586/14760584.2013.811188. Review.

PMID:
23885820
20.

Safety review: squalene and thimerosal in vaccines.

Montana M, Verhaeghe P, Ducros C, Terme T, Vanelle P, Rathelot P.

Therapie. 2010 Nov-Dec;65(6):533-41. Epub 2010 Dec 23. Review.

PMID:
21176760

Supplemental Content

Support Center